



DECEMBER 10–13, 2024

HENRY B. GONZALEZ CONVENTION CENTER • SAN ANTONIO, TX

Program

[Last updated: October 23, 2024]

Tuesday, December 10 (All times are in CST)

Ancillary educational events

8:00 – 9:15 am

Lancet Breast Cancer Session

9:30 – 11:30 am

ABC Global Alliance and US MBC Alliance Communication Session

SABCS Program Begins

12:00 – 1:45 pm

Prevention Special Session: Mechanisms of Obesity Related Risk for Breast Cancer and Approaches to Risk Reduction

Moderator: Carol Fabian, University of Kansas Medical Center, Westwood, Kansas

- Lifestyle, Genetic, and Epigenetic Interactions in Predicting Development of Obesity and Response to Calorie Restriction and Physical Activity
Catherine Duggan, the Fred Hutchinson Cancer Center, Seattle, Washington
- Achieving Sufficient Fat loss and Metabolic Improvement to Reduce Cancer Risk: Newer Generation GLP-1n and GIP Receptor Agonists (Nutrient Sensing Hormone (NUSH) - Based Therapeutics
Neil Iyengar, Memorial Sloan Kettering Cancer Center
- Impact and Types of Exercise and Pharmacotherapy in Weight Loss
John Jakicic, University of Kansas Medical Center, Westwood, Kansas
- **Panel Discussion**

12:00 – 1:45 pm

FDA Special Session: New Drug Approvals

Moderator: To be announced

Patient Advocate: Victoria Goldberg, New York, New York

Speakers to be announced

12:00 – 1:45 pm

Special Session 3: Sex, Drugs, Rock & Roll

Moderator: Christine Ambrosone, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Patient Advocate: Tomika Bryant, King of Prussia, Pennsylvania

- Supplements and Cannabis
Heather Greenlee, Fred Hutchinson Cancer Center, Seattle, Washington

- Sexual Health
Don Dizon, Legorreta Cancer Center at Brown University/Lifespan Cancer Institute, Providence, Rhode Island
- Exercise During Treatment
Rikki Cannioto, Roswell Park Comprehensive Cancer Center, Buffalo, New York
- Alcohol
Marilyn Kwan, Kaiser Permanente Northern California, Pleasanton, California
- **Panel Discussion**

12:00 – 1:45 pm

Career Development: Navigating the Road to Success – Early Funding for Research and Beyond

Moderator: Brenda Ernst, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

- Federal Funding Opportunities
Larissa Korde, Johns Hopkins School of Medicine, Washington, D.C.
- Foundation and Community Program Support
Sara Tolaney, Dana-Farber Cancer Institute, Boston, Massachusetts
- Industry Interactions and Funding Programs
Minetta Liu, Natera, Austin, Texas
- **Panel Discussion**

2:00 – 3:45 pm

Clinical Workshop: Dose Optimization in Breast Medical Oncology

Moderators: Mirat Shah, FDA, Silver Spring, Maryland, and **Patricia**

LoRusso, Yale School of Medicine, New Haven, Connecticut

Patient Advocates: **Julia Maués**, Baltimore, Maryland, and **Debora Denardi**, Miami Beach, Florida

2:00 – 3:45 pm

Translational Workshop: Cancer Immunology Discovery Approaches into Clinical Trials

Moderator: Christine Desmedt, KU Leuven, Leuven, Belgium

- Multiplex Imaging for Precision Oncology
Raza Ali, Cancer Research UK, Cambridge, United Kingdom
- Single Cell T-Cell Receptors and B-Cell Receptors
Diether Lambrechts, Catholic University of Leuven, Leuven, Belgium
- Spatial Transcriptomics
Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium
- Cancer Immunology Discovery Approaches into Clinical Trials
Emanuela Romano, Institut Curie, Paris, France
- **Panel Discussion**

2:30 – 4:00 pm

Career Development: Patient Driven Protocol Development

Moderator: Saranya Chumsri, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida, and **Brenda Ernst**, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

- Importance of Partnerships in Clinical Research
Edith Perez, Mayo Clinic, Kenwood, California

- Designing Patient-centric Clinical Trials
Tatiana Prowell, FDA, Silver Spring, Maryland
- Patient-centered Design
Amylou Dueck, Mayo Clinic Cancer Center, Scottsdale, Arizona

4:00 – 5:45 pm

Educational Session 1: Mind the Gap — Breast Cancer in the Young

Moderator: Matteo Lambertini, University of Genova - IRCCS Ospedale Policlinico, San Martino, Genoa, Italy

Patient Advocate: Na'Diah Smith, Dallas, Texas

- Biology of Breast Cancer in Young Women
Camila Dos Santos, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
- Ovarian Suppression: Who, When, Why, and for How Long
Prudence Francis, Peter MacCallum Cancer Centre, Melbourne, Australia
- Survivorship
Jennifer Sheng, Johns Hopkins University, Baltimore, Maryland
- **Panel Discussion**

4:00 – 5:45 pm

Educational Session 2: Liquid Biopsy: MRD, CT DNA, and Monitoring Response to Treatment

Moderator: Adrian Lee, University of Pittsburgh, Pittsburgh, Pennsylvania

Patient Advocate: Ellen Landsberger, New York City, New York

- Review of Current Technologies
Heather Parsons, Dana-Farber Cancer Institute, Boston, Massachusetts
- Early Detection and Molecular Recurrent Disease
Ben Park, Vanderbilt University Medical Center, Nashville, Tennessee
- Utility in the Metastatic Setting
David Cescon, UHN Princess Margaret Cancer Centre, Toronto, Canada
- **Panel Discussion**

4:00 – 5:45 pm

Educational Session 3: Tumor Heterogeneity and Evolution

Moderator: Reuben S. Harris, UT Health San Antonio, San Antonio, Texas

- Therapy Induced Evolution
Nicholas Navin, UT MD Anderson Cancer Center, Houston, Texas
- Genomic and Microenvironment Determinants of Breast Cancer Progression
Christina Curtis, Stanford University, Stanford, California
- Single Cell Genomics in Triple Negative Breast Cancer
Ashley Laughney, Weill Cornell Medicine, New York, New York
- **Panel Discussion**

4:00 – 5:45 pm

Educational Session 4: Optimizing Early HER2 Positive Breast Cancer Treatment

Moderator: Javier Cortes, International Breast Cancer Center, Barcelona, Spain

Patient Advocate: Thelma Brown, Birmingham, Alabama

- Neoadjuvant Management and Adaptive Strategies
Gabe Sonke, Netherlands Cancer Institute, Amsterdam, Netherlands
- Treatment of Small Tumors in Early-Stage Setting

Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts

- Post Neoadjuvant Management for non pCR
- **Joyce O'Shaughnessy**, Baylor University, Dallas, Texas
- **Panel Discussion**

5:45 – 6:15 pm

Refreshment and Networking Break

6:00 – 7:00 pm

Late Breaking Oral Presentations

Wednesday, December 11 (All times are in CST)

- 7:00 – 8:30 am **Concurrent Poster Spotlight Sessions 1-5**
- 8:30 – 8:35 am **Welcome and Opening Remarks**
- 8:35 – 9:15 am **Keynote Address**
Dr. William Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts
- 9:15 – 11:30 am **General Session 1**
- 11:30 am – 12:00 pm **William L. McGuire Memorial Lecture**
Laura J. van 't Veer, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
- 12:00 – 12:50 pm **Rapid Fire 1**
- 12:30 – 2:00 pm **Poster Session 1**
Halls 2-3
- 12:00 – 1:45 pm **Early Detection**
Moderator: Ismail Jatoi, UT Health San Antonio Mays Cancer Center, San Antonio, Texas
- Risk-Based Screening in the Average Population
Karla Kerlikowske, University of California San Francisco, San Francisco, California
 - Novel Imaging Modalities
Connie Lehman, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts
 - Screening for High-Risk Women
Speaker to be announced
 - **Panel Discussion**
- 1:00 – 1:50 pm **Clinical Case Discussions**
Moderator: Debra Patt, Texas Oncology, Austin, Texas
Patient Advocate: Kelly Shanahan, Tahoe, California
- **Sonya Reid**, Vanderbilt Ingram Cancer Center, Nashville, Tennessee
 - **Icro Meattini**, Florence University Hospital, Florence, Italy
 - **Tari King**, Dana-Farber Cancer Institute, Boston, Massachusetts
 - **Joannie Ivory**, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
 - **Anne Salomon**, Institut Curie, Paris, France
 - **Harold Burstein**, Dana-Farber Cancer Institute, Boston, Massachusetts
- 1:00 – 3:30 pm **Navigating Success: Women's Career Development**

Moderator: Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts

Designed for women who have completed their training and are now in practice, this workshop is a dynamic and inclusive event aimed to inspire and support women pursuing careers in scientific research. The workshop provides a platform for accomplished female scientists to share their experiences, provide mentorship, and discuss strategies to overcome gender-related challenges in the field of cancer research. Through engaging talks, interactive sessions, and networking opportunities, participants gain valuable insights, build a stronger support network, and acquire practical tools to thrive and excel in their scientific research careers.

- Setting the stage for Success
Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts
- Evidence-based strategies to address systemic barriers facing women researchers
Reshma Jagsi, Emory University, Atlanta, Georgia

2:00 – 3:00 pm

State of the Art Session 1: The Winding Road of Immune Biomarkers in Early Breast Cancer

Moderator: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

- TILs: An Update After 10 Years of Research
Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia
- Immune Biomarkers Beyond TILs
Justin Balko, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
- Deploying Immune Biomarkers in Clinical Trials
Priyanka Sharma, University of Kansas Medical Center, Westwood, Kansas
- **Panel Discussion**

2:00 – 3:00 pm

Translational Controversies

Moderator: Antonio Wolff, Johns Hopkins University, Baltimore, Maryland

- How to Define Triple Negative Breast Cancer
Rebecca Dent, National Cancer Center Singapore, Singapore
Charles Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
- Tumor Agnostic Drug Development
Funda Meric, MD Anderson Cancer Center, Houston, Texas
Fabrice Andre, Institut Gustave Roussy, Villejuif, France

3:00 – 3:30 pm

AACR Outstanding Investigator Award for Breast Cancer Research

3:30 – 5:15 pm

Educational Session 5: Unlocking New Targets with Molecular Degradors

Moderator: Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas

- PROTACs

- Lysosome-targeting Chimeras
- Carolyn Bertozzi, Stanford University, Palo Alto, California
- Biparatropic Antibodies
- **Panel Discussion**

3:30 – 5:15 pm

Educational Session 6: Case Based Clinical Approach to ER Positive Metastatic Breast Cancer

Moderator: Sara Hurvitz, Fred Hutch Cancer Center, Seattle, Washington

Case Presentations and Discussants:

Michael Oliphant, Harvard Medical School, Boston, Massachusetts

Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California

Neil Vasan, Columbia University Irving Medical Center, New York, New York

Dan Stover, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Amy Beumer, Patient Advocate, Mason, Ohio

- Case 1: New diagnosis ER+HER2-MBC: genomic considerations
- Case 2: Can we delay CDK4/6i treatment until the second line?
- Case 3: Selecting therapy after progression of disease on CDK4/6i therapy in patients with PI3K pathway mutations
- Case 4: Selecting treatment for patient with tumor ESR1 mutation
- Case 5: When it's time to move on from endocrine approaches, chemo or ADC?

3:30 – 5:15 pm

Educational Session 7: People's Choice - Future Directions in Antibody Drug Conjugates

Speakers to be announced

3:30 – 5:15 pm

Educational Session 8: Optimizing Local Therapy

Moderator: Tari King, Dana-Farber Brigham Cancer Center, Boston, Massachusetts

Patient Advocate: Yvonne Florance, Philadelphia, Pennsylvania

- Let's Talk About PBI
Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York
- Axillary Management: When to Dissect and When to Radiate
Stephanie Wong, Jewish General Hospital Segal Cancer Centre, McGill University Medical School, Montreal, Canada
- Surgical Prevention and Management of Lymphedema
Sarah McLaughlin, Mayo Clinic, Jacksonville, Florida
- Panel Discussion

5:30 – 7:00 p.m.

Poster Session 2

Halls 2-3

Thursday, December 12 (All times are in CST)

- 7:00 – 8:30 am **Concurrent Poster Spotlight Sessions 6-10**
- 8:30 – 9:00 am **Plenary Lecture**
- The Grand Challenge of Unraveling Social vs Biological Drivers of Racial Disparities in Cancer Outcomes
Melissa B. Davis, Morehouse School of Medicine, Atlanta, Georgia
- 9:00 – 11:45 am **General Session 2**
- 12:00 – 12:50 pm **Rapid Fire 2**
- 12:30 – 2:00 pm **Poster Session 3**
Halls 2-3
- 12:30 – 1:45 pm **The Future of Cancer Genetics Is Here**
Moderator: Claudine Isaaks, Georgetown University, Washington, DC
Patient Advocate: Tanja Spanic, Europa Donna Slovenia, Ljubljana, Slovenia
- Saturation Genome Editing-Based Functional and Clinical Classification of VUS in BRCA2
Fergus Couch, Mayo Clinic, Rochester, Minnesota
 - Updates on Risk Prediction Models
Antonis Antoniou, Cancer Research UK Cambridge Center, Cambridge, United Kingdom
 - Reversion Mutations in BRCA1/2 in Response to Therapy
Katherine Nathanson, University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
 - **Panel Discussion**
- 1:00 – 1:50 pm **Molecular Tumor Board**
Moderator: Phillipe Afthimos, Insitut Jules Bordet, Brussels, Belgium
- **Dara Aisner**, University of Colorado Medical School, Aurora, Colorado
 - **Jorge Reis-Filho**, AstraZeneca, Gaithersburg, Maryland
 - **Philippe Bedard**, Princess Margaret Cancer Centre, Toronto, Canada
 - **Jenna Canzoniero**, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland
 - **Bob Riter**, Cornell University, Ithaca, New York
- 2:00 – 3:00 pm **Clinical Controversies: Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies**
Moderator: Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, New York
- Omission of Axillary Staging in ER+ Disease: What is The Data?
Elizabeth Mittendorf, Dana-Farber Cancer Institute, Boston, Massachusetts
 - Omission of Axillary Staging in ER+ Disease: Implications for Radiotherapy
Jean Wright, UNC School of Medicine, Chapel Hill, North Carolina

- Omission of Axillary Staging in ER+ Disease: Implications for Adjuvant Systemic Therapy
Kevin Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia
- Radiation Post pCR
Richard Zellars, Indiana University School of Medicine, Indianapolis, Indiana
- **Panel Discussion**

2:00 – 3:00 pm

State of the Art: Revolutionizing Diagnosis and Discovery with Artificial Intelligence**Moderator: Fred Howard**, University of Chicago, Chicago, Illinois

- Pathology
Speaker to be announced
- Imaging and Screening
Ritse Mann, Netherlands Cancer Institute, Amsterdam, Netherlands
- Drug Discovery, Deep Learning, and Large Data Management
Speaker to be announced
- **Panel Discussion**

3:00 – 3:30 pm

AACR Distinguished Lecture in Breast Cancer Research

3:30 – 5:15 pm

Educational Session 9: Artificial Intelligence in the Clinic**Moderator: Debra Patt**, Texas Oncology-Austin Central, Austin, Texas

Patient Advocate: Kay Firth-Butterfield, Austin, Texas

- Hazards and Opportunities
Andrew Hantel, Dana-Faber Cancer Institute, Boston, Massachusetts
- Beyond Chat GPT: Generative AI in Healthcare
Ian Maurer, Genomoncology, Cleveland, Ohio
- Digital Tools for Clinical Practice
Emily Ray, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
- **Panel Discussion**

3:30 – 5:15 pm

Educational Session 10: Immunotherapy**Moderator: Heather McArthur**, UT Southwestern Medical Center, Dallas, Texas

- Immunotherapy in Early ER Positive Breast Cancer
Cesar Santa Maria, John Hopkins Medicine, Baltimore, Maryland
- Optimization of Treatment in TNBC
Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands
- The Future of Immunotherapy
Evanthia Roussos Torres, University of Southern California, Los Angeles, California
- **Panel Discussion**

3:30 – 5:15 pm

Educational Session 11: Mind the Gap — Breast Cancer in Older Adults

Moderator to be announced

Patient Advocate: Sandi Stanford, San Antonio, Texas

- The Aging Immune System with Hormonal Changes
Speaker to be announced

- Defining and Avoiding Low Value Surgical Therapy
Christina Minami, Brigham and Women's Hospital, New York, New York
- Systemic Therapies
Hans Wildiers, University Hospital Leuven, Leuven, Belgium
- **Panel Discussion**

3:30 – 5:15 pm

Educational Session 12: The Biology and Treatment Implications of Organ Specific Metastases**Moderator: Heide Ford**, University of Colorado Denver School of Medicine, Denver, Colorado

Patient Advocate: Christine Hodgdon, Baltimore, Maryland

- Brain Metastases
Diana Cittelly, University of Colorado Anschutz Medical Campus, Aurora, Colorado
- Liver Metastases
Peter Vermeulen, GZA Hospital Sint-Augustinus, Antwerp, Belgium
- Bone Metastases
Rachelle Johnson, Vanderbilt University Medical Center, Nashville Tennessee
- **Panel Discussion**

5:30 – 7:00 pm

Poster Session 4

Halls 2-3

5:30 – 7:00 pm

Concurrent Poster Spotlight Sessions 16-18

8:00 – 10:30 pm

SABCS Celebration

Texas Ballroom, Grand Hyatt San Antonio Hotel

Friday, December 13 (all times are in CST)

- 7:00 – 8:30 am **Concurrent Poster Spotlight Sessions 11-15**
- 8:30 – 9:00 am **Plenary Lecture**
- Cell Atlases as Roadmaps in Cancer Immunology
Walid Khaled, University of Cambridge, Cambridge, United Kingdom
- 9:00 – 11:45 am **General Session 3**
- 12:00 – 12:50 pm **Rapid Fire 3**
- 12:30 -2:00 pm **Poster Session 5**
Halls 2-3
- 12:30 – 2:00 pm **The Pathologists Conundrum: IHC Testing in Breast Cancer**
Moderator: **David Rimm**, Yale School of Medicine, New Haven, Connecticut
- A Brief History of IHC in Breast Cancer and ASCO CAP Guidelines
Kim Allison, Stanford University/Stanford Cancer Institute, Palo Alto, California
 - The FDA’s Perspective: What is Required for a Companion Diagnostic Test
Reena Philips, FDA, Gaithersburg, Maryland
 - Evaluation of the accuracy of Reading IHC
Giuseppe Viale, European Institute of Oncology, Milan, Italy
 - Evaluation of the Accuracy of Digital Measuring
Andrew Beck, Path AI
- 12:30 – 1:45 pm **New Directions in Breast Cancer Prevention**
Moderator: **Gretchen Gierach**, National Cancer Institute, Bethesda, Maryland
- Prevention Vaccines: Where Are We Now and Where Are We Going?
Olivera Finn, University of Pittsburgh, Pittsburgh, Pennsylvania
 - Can We Use Biomarkers to Implement Prevention?
Seema Khan, Feinberg School of Medicine of Northwestern University, Chicago, Illinois
 - From Bench to Clinical Trial: A New Target for Breast Cancer Prevention
Geoff Lindeman, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
 - **Panel Discussion**
- 2:00 – 2:50 pm **Debate: All Patients Should be Offered Universal Germline Genetic Testing**
Moderator: **Virginia Kaklamani**, UT Health San Antonio, San Antonio, Texas
- Opening Remarks and Polling
 - Debate For
Allison Kurian, Stanford University, Stanford, California
 - Debate Against
Raymond Kim, UHN Princess Margaret Cancer Centre, Toronto, Canada
 - Closing Remarks and Polling

3:00 – 5:00 pm

Year in Review

Moderators: **Carlos Arteaga**, UT Southwestern Medical Center, Dallas, Texas; and **Virginia Kaklamani**, UT Health San Antonio, San Antonio, Texas

- Translational Science Updates
Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York
- Early Breast Cancer Updates
Janice Tsang, University of Hong Kong, Hong Kong
- Advanced Breast Cancer Updates
Michael Danso, Virginia Oncology Associates, Norfolk, Virginia
Basic Science
- **Neil Vasan**, Columbia University, New York, New York

5:00 – 5:30 pm

Reception Break

5:30 – 7:00 pm

View from the Trenches

Moderator: **Joyce O’Shaughnessy**, UT Health San Antonio, San Antonio, Texas